Savara (SVRA) – Research Analysts’ Weekly Ratings Updates

Savara (NASDAQ: SVRA) recently received a number of ratings updates from brokerages and research firms:

  • 4/11/2019 – Savara was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $10.00 price target on the stock. According to Zacks, “Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. “
  • 4/5/2019 – Savara was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 4/1/2019 – Savara was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 4/1/2019 – Savara had its “buy” rating reaffirmed by analysts at LADENBURG THALM/SH SH. They now have a $21.00 price target on the stock.
  • 3/25/2019 – Savara was given a new $22.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 3/14/2019 – Savara was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. “
  • 3/12/2019 – Savara was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 3/8/2019 – Savara was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. “
  • 3/2/2019 – Savara was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. “
  • 2/21/2019 – Savara was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. “

Shares of Savara stock opened at $9.32 on Monday. Savara Inc has a 12-month low of $6.21 and a 12-month high of $14.06. The firm has a market capitalization of $333.94 million, a PE ratio of -7.22 and a beta of 0.86. The company has a quick ratio of 15.63, a current ratio of 15.63 and a debt-to-equity ratio of 0.23.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Wednesday, March 13th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.08. As a group, research analysts expect that Savara Inc will post -1.55 earnings per share for the current year.

In related news, insider Jaakko Taneli Jouhikainen sold 25,000 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $9.03, for a total value of $225,750.00. Following the completion of the sale, the insider now owns 184,754 shares in the company, valued at approximately $1,668,328.62. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO David L. Lowrance sold 7,500 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $9.02, for a total transaction of $67,650.00. Following the completion of the sale, the chief financial officer now owns 2,446 shares of the company’s stock, valued at approximately $22,062.92. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,761 shares of company stock valued at $385,749. 6.10% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp raised its position in Savara by 3.5% in the 4th quarter. Bank of New York Mellon Corp now owns 82,940 shares of the company’s stock valued at $628,000 after purchasing an additional 2,830 shares during the last quarter. Simplex Trading LLC raised its position in Savara by 246.1% in the 4th quarter. Simplex Trading LLC now owns 4,997 shares of the company’s stock valued at $37,000 after purchasing an additional 3,553 shares during the last quarter. MetLife Investment Advisors LLC raised its position in Savara by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 20,243 shares of the company’s stock valued at $226,000 after purchasing an additional 7,196 shares during the last quarter. Teachers Advisors LLC raised its position in Savara by 15.0% in the 3rd quarter. Teachers Advisors LLC now owns 55,053 shares of the company’s stock valued at $614,000 after purchasing an additional 7,198 shares during the last quarter. Finally, Alliancebernstein L.P. purchased a new stake in Savara in the 3rd quarter valued at $118,000. Hedge funds and other institutional investors own 48.42% of the company’s stock.

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

See Also: Coverage Ratio

Receive News & Ratings for Savara Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara Inc and related companies with MarketBeat.com's FREE daily email newsletter.